ACEA Biosciences – A Part of Agilent Launches the xCELLigence RTCA ePacer to improve the Quality & Functionality of hiPSC-C...
April 16 2019 - 7:00AM
Business Wire
The new xCELLigence RTCA ePacer provides a solution that uses
electrical pacing to functionally mature cardiomyocytes.
On March 11, 2019, ACEA Biosciences – A Part of Agilent unveiled
the new xCELLigence® RTCA ePacerTM during their workshop held at
the Society of Toxicology (SOT) Annual Meeting in Baltimore.
Human induced pluripotent stem cell cardiomyocytes (hiPSC-CM)
are increasingly being used as a human-relevant in vitro model
system for drug discovery, safety pharmacology, and cardiac disease
research. While these cells are “fit for purpose” for a number of
applications, their inherent immature phenotype has limited their
applicability for many in vitro studies.
“The challenge with hiPSC cardiomyocytes is that they are more
like neonatal cardiomyocytes rather than adult-like
cardiomyocytes,” said Yama Abassi, Ph.D., Vice President of ACEA
Biosciences – A Part of Agilent. It is imperative to improve the
maturation status and functionality of hiPSC-CM in order to obtain
a more relevant and predictive model system that can be used for
downstream applications. While there are a number of techniques
being investigated, prolonged electrical pacing has been shown to
be an efficient and reliable way to enable functional maturation of
hiPSC-CM. The xCELLigence ePacer allows for a scalable, efficient,
and high throughput method for maturing hiPSC-CM in vitro.
Moreover, the specially designed microelectronic plates (E-Plates)
are compatible with other orthogonal readouts such as calcium and
high content imaging.
Built upon the same groundbreaking technology of the xCELLigence
RTCA Cardio and CardioECR systems, the xCELLigence RTCA ePacer uses
electrical stimuli to precisely stimulate and pace cardiomyocytes
cultured in E-Plates. With the pacing protocols on the ePacer,
researchers can produce functionally mature cardiomyocytes within
1-3 weeks, depending on the cardiomyocyte types and the pacing
protocol details. Importantly, after pacing is performed, the
ePacer software is able to generate metrics to verify the extent of
maturity of the paced cardiomyocytes. These functionally matured
cardiomyocytes have much improved responses to inotropic compounds
and are more predictive of ion channel modulators. In addition, a
number of relevant ion channels, structural proteins, and
sarcomeric proteins are upregulated in these paced and functionally
mature cardiomyocytes.
The xCELLigence RTCA ePacer is designed to be part of an
integral workflow and to revolutionize the way scientists use
hiPSC-CM for their research. “By providing researchers access to
cardiomyocytes with characteristics that match more closely to
human adult heart cells,” says Dr. Abassi, “we believe that the
ePacer will give them more confidence in their assays.
About xCELLigence® Real Time Cell Analysis (RTCA)
ACEA’s xCELLigence RTCA instruments are being used in both
academia and industry for life science applications ranging from
cancer immunotherapy, bacterial biofilms, vaccine development and
cardiotoxicity testing. With the xCELLigence technology, scientists
can non-invasively monitor the behavior of cells by quantifying
cell proliferation, morphology change, and attachment quality in a
label-free, real-time manner.
About ACEA Biosciences, A Part of Agilent
Technologies
ACEA Biosciences, a part of Agilent Technologies, is a pioneer
in the development and commercialization of high-performance cell
analysis platforms for life science research. ACEA’s xCELLigence®
Real-Time Cell Analysis instruments and NovoCyte® Quanteon flow
cytometers are used in pre-clinical drug discovery and development,
toxicology, safety pharmacology, and basic academic research. More
than 3,000 instruments have been placed globally, and have been
used in more than 2,000 peer-reviewed publications. For more
information visit: http://www.aceabio.com. Follow
on LinkedIn, Twitter, and Facebook.
About Agilent Technologies
Agilent Technologies Inc. (NYSE: A) is a global leader in life
sciences, diagnostics, and applied chemical markets. Based on more
than 50 years of insight and innovation, Agilent instruments,
software, services, solutions, and people provide trusted answers
to customers’ most challenging questions. The company generated
revenues of $4.91 billion in fiscal 2018 and employs 14,800 people
worldwide. Information about Agilent is available at
http://www.agilent.com. To receive the latest Agilent news,
subscribe to our Newsroom. Follow Agilent
on LinkedIn, Twitter, and Facebook.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190416005193/en/
ACEA Biosciences, Inc., a part of AgilentDr. Jeff XuePhone:
858-299-8023email: jxue(at)aceabio(dot)com
Agilent Technologies (NYSE:A)
Historical Stock Chart
From Apr 2024 to May 2024
Agilent Technologies (NYSE:A)
Historical Stock Chart
From May 2023 to May 2024